The global amyloidosis therapeutics market size was valued at USD 2.94 billion in 2024 and is projected to cross around 6.45 billion by 2034, growing at a CAGR of 8.18% from 2025 to 2034.

Get Sample Copy of Report@ https://www.precedenceresearch.com/sample/5710

Key Insights

• North America led the global market with a 47% share in 2024.
• Asia Pacific is expected to grow at the fastest CAGR between 2025 and 2034.
• The chemotherapy segment accounted for the largest market share in 2024.
• The transplantation segment is projected to experience significant growth from 2025 to 2034.
• Hospitals and clinics held the largest market share among end users in 2024.
• The home care settings segment is expected to witness the highest growth during the forecast period.

AI Driving Innovation and Efficiency in Amyloidosis Therapeutics

• AI-assisted imaging and histopathology analysis improve the accuracy of amyloidosis diagnosis at an early stage.
• AI-driven genomic sequencing helps identify genetic predispositions, paving the way for targeted and gene-based treatments.
• Predictive modeling assists in understanding protein misfolding mechanisms, a crucial aspect of amyloidosis progression.
• AI-powered supply chain management ensures the efficient distribution of life-saving drugs and medical resources.
• Machine learning enhances patient stratification, ensuring that treatments are personalized for maximum efficacy.
• AI-supported telemedicine platforms expand access to specialists, improving care for patients in remote and underserved areas.

Growth Factors:

• Increasing Disease Prevalence: The rising incidence of amyloidosis, particularly among the aging population, has heightened the demand for effective therapeutic options.​

• Advancements in Diagnostic Techniques: Improvements in diagnostic procedures have facilitated earlier detection of amyloidosis, leading to timely interventions and better patient outcomes.​

• Development of Novel Therapies: Ongoing research and development efforts have resulted in innovative treatment modalities, including targeted therapies and monoclonal antibodies, enhancing the efficacy of amyloidosis management.​

• Increased Awareness and Screening: Growing awareness among healthcare professionals and patients has led to more frequent screenings, contributing to early diagnosis and treatment.​

Regional Outlook:

• North America: In 2024, North America dominated the global amyloidosis therapeutics market, accounting for a 47% share. This leadership is attributed to a well-established healthcare infrastructure, high awareness levels, and substantial investment in research and development.​

• Asia Pacific: The Asia Pacific region is projected to experience the fastest compound annual growth rate (CAGR) between 2025 and 2034. Factors such as improving healthcare facilities, increasing healthcare expenditure, and a growing patient population contribute to this rapid expansion.​

• Europe: Europe holds a significant share of the amyloidosis therapeutics market, driven by advanced diagnostic capabilities and a strong emphasis on rare disease management. The region’s focus on healthcare innovation supports market growth.​

• Latin America and Middle East & Africa: These regions are gradually emerging in the amyloidosis therapeutics market, with increasing awareness and improving healthcare infrastructures. However, challenges such as limited access to advanced treatments and economic constraints may affect growth rates.

Also Read: Off-Highway Electric Vehicle Market

Market Scope

Report Coverage	Details
Market Size by 2034	USD 6.45 Billion
Market Size in 2025	USD 3.18 Billion
Market Size in 2024	USD 2.94 Billion
Market Growth Rate from 2025 to 2034	CAGR of 8.18%
Dominated Region	North America
Fastest Growing Market	Asia Pacific
Base Year	2024
Forecast Period	2025 to 2034
Segments Covered	Treatment, End User, and Regions.
Regions Covered	North America, Europe, Asia-Pacific, Latin America and Middle East & Africa

Market Dynamics

Market Drivers

Key factors driving the amyloidosis therapeutics market include improved disease awareness, technological advancements in diagnostics, and increasing research into protein misfolding disorders. The availability of novel treatment options, including gene therapy and monoclonal antibodies, is enhancing patient outcomes and boosting market demand.

Market Opportunities

Advancements in AI and machine learning are revolutionizing drug discovery and personalized medicine in amyloidosis treatment. The expansion of clinical trials in emerging markets provides new opportunities for pharmaceutical companies. Additionally, patient advocacy groups and non-profit organizations are playing a crucial role in raising awareness and driving funding for research.

Market Challenges

The heterogeneity of amyloidosis makes treatment difficult, as different subtypes require distinct therapeutic approaches. A lack of standardized treatment guidelines creates inconsistencies in disease management across regions. Furthermore, the high cost and limited availability of specific therapies restrict access for many patients.

Amyloidosis Therapeutics Market Companies

• Alnylam Pharmaceuticals, Inc.
• Amgen Inc.
• Bristol-Myers Squibb Company
• F. Hoffmann-La Roche Ltd
• GSK plc.
• Takeda Pharmaceutical Company Limited
• Sanofi
• Pfizer Inc.
• Johnson & Johnson Services, Inc.
• Merck KGaA
• Novartis AG
• Ionis Pharmaceuticals

Leader’s Announcements

• In March 2025, Ionis Pharmaceuticals Inc., announced the European Union’s approval for Ionis and AstraZeneca’s WAINZUA (eplontersen). Brett P. Monia, Chief Executive Officer, Ionis, said that, “Today’s approval of WAINZUA in Europe offers adults with hereditary transthyretin-mediated amyloidosis with polyneuropathy a new, self-administered treatment option that provides consistent suppression of transthyretin production and improves neuropathy impairment and quality of life. With approvals in North America, UK and now across the EU, we are proud of the continued progress as we and our partner, AstraZeneca, rapidly and effectively deliver WAINZUA to people around the world.”

Recent Developments

• In February 2025, Paradox Immunotherapeutics, a pharmaceutical company developing innovative antibody therapies, secured a $10 million investment in a financing round led by SymBiosis which is an investment firm concentrated on advancing biotherapeutics innovations for serious and life-threatening diseases. The funding will focus on advancing therapies for protein misfolding diseases and accelerating candidates for immunoglobulin light chain amyloidosis (AL amyloidosis) and leukocyte chemotactic factor 2 amyloidosis (LECT2).
• In July 2024, Kisunla which is a first-of-a-kind amyloid plaque removal therapy developed by Eli Lilly and Company for treatment of adults with early symptoms of Alzheimer’s disease and confirmed amyloid pathology received approval from the U.S. FDA.

Segments Covered in the Report

By Treatment

• Chemotherapy
• Immunosuppressive Drugs
• Transplantation
• Supportive Care
• Surgery
• Others

By End User

• Hospitals & Clinics
• Ambulatory Surgical Centers
• Home Care Settings
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Ready for more? Dive into the full experience on our website@ https://www.precedenceresearch.com/